Galapagos Division to Make Cell-based Assays for Dart Drug Program | GenomeWeb
NEW YORK (GenomeWeb News) – Galapagos’ service division, BioFocus DPI, will make cell-based assays for Dart Neuroscience, which will use them in its drug discovery programs for brain disorders, Galapagos said today.
 
The three-year collaboration is potentially worth €4.1 million ($5.4 million) to Galapagos, the Mechelen, Belgium-based firm said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.